Salarius Pharmaceuticals – Consensus Indicates Potential 433.7% Upside

Broker Ratings

Salarius Pharmaceuticals found using ticker (SLRX) now have 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The range between the high target price and low target price is between 5 and 3.8 with a mean TP of 4.43. With the stocks previous close at 0.83 this would indicate that there is a potential upside of 433.7%. The 50 day moving average now sits at 0.81 and the 200 day MA is 1.03. The market capitalisation for the company is $16m. Find out more information at:

Salarius Pharmaceuticals a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company’s lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index